

08/812,508

-2-

5117-C1-01-MG


**Amendments to the Claims:**

This listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-72 (cancelled)

73. (New): A compound of Formula I:



Formula I

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is



-NH-C-NH ; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl.

74. (New): A pharmaceutically acceptable salt of the compound of claim 73.


75. (New): A pharmaceutical composition comprising the compound of claim 73 and a pharmaceutically acceptable carrier.

76. (New): A compound having the structure and meanings for R as indicated:

08/812,508

-3-

5117-C1-01-MG



wherein R is selected from the group consisting of:

- a) 4-BrPh;
- b) 4-COOEt-Ph;
- c) 4-CF<sub>3</sub>Ph;
- d) 3-Me-Ph;
- e) 3-COOEt-Ph;
- f) 3-COOtBu-Ph;
- g) 3-COOH-Ph;
- h) 4-MeO-Ph;
- i) 3-MeO-Ph; and
- j) 2-MeO-Ph.

77. (New): A compound selected from:

Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-ethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[(4-trifluoromethyl)phenyl]-;

08/812,508

-4-

5117-C1-01-MG

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)-;


Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-ethyl ester;

Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-ethyl ester;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-; and

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-1,1-dimethylethyl ester.

78. (New): A compound of Formula I:



Formula I

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is



-NH-C-NH ; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from

- hydrogen





5117-C1 Response Ntc Non-Compliance 4-30-2004

08/812,508

-5-

5117-C1-01-MG

- lower alkyl of 1-4 carbon atoms,
- $(\text{CH}_2)_1\text{OR}_{13}$
- $(\text{CH}_2)_1\text{SR}_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl





5117-C1 Response Ntc Non-Compliance 4-30-2004


08/812,508

-6-

5117-C1-01-MG



and




wherein *i* and *j* are independently 0, 1, 2,

*R*<sub>13</sub>, *R*<sub>14</sub>, *R*<sub>15</sub>, *R*<sub>16</sub> are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

*N*<sub>*R*<sub>13</sub>*R*<sub>14</sub></sub> is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

79. (New): A method for treating a condition advantageously affected by the binding of the compound of Formula I to a CCK receptor in a mammal in need of such treatment comprising providing an effective binding amount of the compound of Formula I:



Formula

I

08/812,508

-7-

5117-C1-01-MG

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;



M is oxygen;

A is  $\begin{array}{c} \text{O} \\ || \\ -\text{NH}-\text{C}-\text{NH}- \end{array}$  and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from





- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>4</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>4</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl




08/812,508

-8-

5117-C1-01-MG



and



wherein i and j are independently 0, 1, 2,

R<sub>13</sub>, R<sub>14</sub>, R<sub>15</sub>, R<sub>16</sub> are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

NR<sub>13</sub>R<sub>14</sub> is also mono or bicyclic ring with one to four hetero atoms as N, O, S.


5117-C1 Response Ntc Non-Compliance 4-30-2004

08/812,508

-9-

5117-C1-01-MG

80. (New): A method of reducing gastric acid secretion in a mammal comprising administering an effective gastric acid secretion reducing amount to a mammal in need thereof a compound of Formula I:



Formula I

wherein W, X, Y, and

Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is  $\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-NH-} \end{array}$ ; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from







- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>i</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>i</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



08/812,508

-10-

5117-C1-01-MG




5117-C1 Response Nic Non-Compliance 4-30-2004

08/812,508

-11-

5117-C1-01-MG


and



wherein  $i$  and  $j$  are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alky,  
 alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four  
 hetero atoms as N, O, S.

81. (New): A method of reducing anxiety in a mammal,  
 comprising administering an effective anxiety reducing amount to  
 a mammal in need thereof a compound of Formula I:




Formula I

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;  
 R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is



-NH-C-NH; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from





- hydrogen

08/812,508

-12-

5117-C1-01-MG

- lower alkyl of 1-4 carbon atoms,
- $(\text{CH}_2)_4\text{OR}_{13}$
- $(\text{CH}_2)_4\text{SR}_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl





5117-C1 Response Ntc Non-Compliance 4-30-2004


08/812,508

-13-

5117-C1-01-MG



and




wherein  $i$  and  $j$  are independently 0, 1, 2,

$R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

82. (New): A method for treating gastrointestinal ulcers in a mammal comprising administering an effective gastrointestinal ulcer treating amount to a mammal in need thereof a compound of Formula I:



Formula

I

08/812,508

-14-

5117-C1-01-MG

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;



A is  $\begin{array}{c} \text{O} \\ || \end{array}$

-NH-C-NH; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from





- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>1</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>1</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl




08/812,508

-15-

5117-C1-01-MG



and



wherein *i* and *j* are independently 0, 1, 2,  
*R*<sub>13</sub>, *R*<sub>14</sub>, *R*<sub>15</sub>, *R*<sub>16</sub> are each independently hydrogen, lower alky,  
 alkaryl of from 7 to 10 carbon atoms; and

*NR*<sub>13</sub>*R*<sub>14</sub> is also mono or bicyclic ring with one to four  
 hetero atoms as N,O,S.


5117-C1 Response Ntc Non-Compliance 4-30-2004

08/812,508

-16-

5117-C1-01-MG

83. (New): A method of treating psychosis in a mammal comprising administering an effective psychosis in a mammal comprising administering an effective psychosis treating amount to a mammal in need thereof a compound of Formula I:



Formula


I

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is



R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein







the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>1</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>1</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

08/812,508

-17-

5117-C1-01-MG






08/812,508

-18-

5117-C1-01-MG

and




wherein i and j are independently 0, 1, 2,

$R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alkyl, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

84. (New) A method of blocking drug or alcohol withdrawal reaction in a mammal comprising administering an effective withdrawal reaction blocking amount to a mammal in need thereof a compound of Formula I:



Formula

I

wherein W, X, Y, and Z are C- $R_3$ , C- $R_4$ , C- $R_5$ , and C- $R_6$ ;  
 $R_3$ - $R_6$  are hydrogen;

M is oxygen;

A is



and

$R_1$  and  $R_2$  are substituted phenyl, wherein




the substitutions are selected from

08/812,508

-19-

5117-C1-01-MG




- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(\text{CH}_2)_i\text{OR}_{13}$
- $(\text{CH}_2)_i\text{SR}_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl




08/812,508

-20-

5117-C1-01-MG



and



wherein *i* and *j* are independently 0, 1, 2,

*R*<sub>13</sub>, *R*<sub>14</sub>, *R*<sub>15</sub>, *R*<sub>16</sub> are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and


*NR*<sub>13</sub>*R*<sub>14</sub> is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

85. (New): A method of treating pain in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I:

08/812,508

-21-

5117-C1-01-MG



Formula

I

wherein wherein

W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is




and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from






- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>4</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>4</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



08/812,508

-22-

5117-C1-01-MG




and

08/812,508

-23-


5117-C1-01-MG



wherein  $i$  and  $j$  are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alky,  
 alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four  
 hetero atoms as N,O,S.

86. (New): A method of treating panic in a mammal  
 comprising administering an effective amount to a mammal in need  
 thereof a compound of Formula I:



Formula I

wherein W, X, Y,

and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is  $\begin{array}{c} O \\ | \end{array}$

$-NH-C-NH$ ; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from






- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_1OR_{13}$

08/812,508

-24-

5117-C1-01-MG

- $(CH_2)_iSR_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl




5117-C1 Response Ntc Non-Compliance 4-30-2004


08/812,508

-25-

5117-C1-01-MG




and



wherein  $i$  and  $j$  are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alky,  
 alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four  
 hetero atoms as N,O,S.

87. (New): A method of diagnosis of gastrin-dependent tumors  
 in a mammal, comprising administering to the mammal in need  
 thereof an effective diagnosing amount of a radiolabelled iodo  
 compound of Formula I:



Formula I

wherein W, X, Y,  
 and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;



08/812,508

-26-




5117-C1-01-MG

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is  $\begin{array}{c} \text{O} \\ \parallel \end{array}$  $-\text{NH}-\text{C}-\text{NH}-$ ; andR<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>1</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>1</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl






5117-C1 Response Ntc Non-Compliance 4-30-2004


08/812,508

-27-

5117-C1-01-MG



and



wherein i and j are independently 0, 1, 2,

$R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alkyl, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N, O, S.


88. (New): A pharmaceutical composition comprising an effective therapeutical amount of the compound of Formula I and a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier and unit dosage form wherein the therapeutic indication is selected from the group consisting of an appetite

08/812,508

-28-

5117-C1-01-MG

suppressant, a gasteric acid secretion reducing agent, an anxiety reducing agent, a gasterointestinal ulser treating agent, a phycosis treating agent, a with drawal reaction blocking agent, a pain treatment agent, an agent for treating or preventing panic, an agent for treating gasterin dependent tumors




Formula

I

Wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>; R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is



R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein







the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>4</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>4</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

08/812,508

-29-

5117-C1-01-MG




08/812,508

-30-

5117-C1-01-MG

and



wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alky,  
 alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four  
 hetero atoms as N,O,S; provided that  $R_2$  is monosubstituted  
 phenyl.